Healthcare tech company Omnicell (NASDAQ:OMCL) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 7.4% year on year to $312.2 million. On the other hand, next quarter’s revenue guidance of $304 million was less impressive, coming in 2.9% below analysts’ estimates. Its non-GAAP profit of $0.94 per share was significantly above analysts’ consensus estimates.
Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ:OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency.
Omnicell was profitable over the last five years but held back by its large cost base. Its average adjusted operating margin of 9.3% was weak for a healthcare business.
Looking at the trend in its profitability, Omnicell’s adjusted operating margin decreased by 3.8 percentage points over the last five years, but it rose by 4.7 percentage points on a two-year basis. Still, shareholders will want to see Omnicell become more profitable in the future.
Omnicell's EPS declined by 6.2% annually over the last five years while its revenue grew by 4.8%. This tells us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes.
In Q2, Omnicell reported adjusted EPS of $0.94, up from $0.45 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Omnicell’s full-year EPS to shrink by 19.8% from $2.40 to $1.92.
Omnicell beat analysts’ EPS expectations this quarter. We were also glad its full-year EBITDA guidance trumped Wall Street’s estimates. On the other hand, its revenue guidance for next quarter missed and its EPS guidance for next quarter fell short of Wall Street’s estimates.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.